Characteristics of the studies included in meta-analysis
Study | Country | Study months | Sample size | Blood sampled (n) | ART types | Drug dose | Subjects types | Transmission modes | Gender | Median age (range), years | Jadad scale score |
Choopanya et al 14 | Thailand | 84 | 2413 | 138 | TDF | Daily | PWID | Needles/syringe | Both | 31 (20–60) | 5 |
Van Damme et al 4 | Tanzania, South Africa, Kenya | 12 | 2056 | 95 | TDF-FTC | Daily | Women | Vaginal | Women | 24.2 (18–35) | 3 |
Molina et al 12 | France, Canada | 24 | 400 | 113 | TDF-FTC | Intermittent | MSM | Rectal | Men | 34.5 (NA) | 3 |
Grant et al 15 | Peru, Ecuador, South Africa, Brazil, Thailand, USA | 31 | 2499 | 43 | TDF-FTC | Daily | MSM and transgender | Rectal | Men | 27.1 (18–67) | 5 |
Baeten et al 16 | Kenya, Uganda | 36 | 4747 | 902 | TDF-FTC | Daily | Serodiscordant couples | Vaginal/penile | Both | NA (18–45) | 2 |
Baeten et al 16 | Kenya, Uganda | 36 | 4747 | 902 | TDF | Daily | Serodiscordant couples | Vaginal/penile | Both | NA (18–45) | 2 |
Baeten et al 31 | Kenya, Uganda | 36 | 4410 | 81 | TDF-FTC | Daily | serodiscordant couples | vaginal/penile | Both | 34 (28–40) | 2 |
Baeten et al 31 | Kenya, Uganda | 36 | 4410 | 149 | TDF | Daily | Serodiscordant couples | Vaginal/penile | Both | 33 (29–40) | 2 |
McCormack et al 32 | England | 20 | 544 | NA | TDF-FTC | Immediate | MSM | Rectal | Men | 35 (NA) | 5 |
Thigpen et al 33 | Botswana | 42 | 1219 | 69 | TDF-FTC | Daily | Sexually active heterosexual adults | Vaginal/penile | Both | NA (18–39) | 3 |
Marrazzo et al 3 | South Africa, Uganda, Zimbabwe | 33 | 4969 | 158 | TDF | Daily | Women | Vaginal | Women | 25.3 (18–45) | 2 |
Marrazzo et al 3 | South Africa, Uganda, Zimbabwe | 33 | 4969 | 157 | TDF-FTC | Daily | Women | Vaginal | Women | 25.3 (18–45) | 2 |
Peterson et al 34 | Nigeria, Cameroon, Ghana | 12 | 936 | NA | TDF | Daily | Women | Vaginal | Women | 23.5 (18–34) | 5 |
ART, antiretroviral therapy; PWID, people who inject drugs; MSM, men who have sex with men; NA, not available; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.